ClinicalTrials.gg
RecruitingNCT07861633Updated Oct 8, 2026

Cesarean Anesthesia Blood Gas

An observational study in Cesarean Delivery, sponsored by Bagcilar Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Bagcilar Training and Research Hospital · Observational

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
134
Ages
18 Years and older
Sex
Female
01

Study summary

This prospective observational cohort study will evaluate maternal and fetal blood gas parameters in women undergoing cesarean delivery under spinal or general anesthesia. Maternal venous blood samples will be obtained immediately before anesthesia induction, and umbilical arterial blood samples will be obtained after delivery and cord clamping. Blood gas parameters, including pH, pCO2, pO2, bicarbonate, base excess, lactate, and fetal carboxyhemoglobin levels, will be compared between the spinal and general anesthesia groups. The study will also evaluate maternal-fetal blood gas gradients, Apgar scores, neonatal intensive care requirements, and the relationship between smoking exposure and fetal carboxyhemoglobin levels.

02

Conditions studied

  • Cesarean Delivery
03

In context

Lead sponsor

Bagcilar Training and Research Hospital is the lead sponsor of 56 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant women undergoing cesarean delivery at the Obstetrics and Gynecology Clinic of Bagcilar Training and Research Hospital. The study is a prospective observational cohort comparing maternal and fetal blood gas parameters and fetal carboxyhemoglobin levels according to the observed anesthesia technique (spinal or general anesthesia).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult women undergoing cesarean delivery at the study center.
  • Patients receiving spinal or general anesthesia for cesarean delivery.

Exclusion criteria

Exclusion Criteria:

  • Patients who are not eligible for participation according to the study protocol.
  • Patients in whom spinal anesthesia is converted to general anesthesia because of inadequate spinal block and pain during surgery.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
134 participants (estimated)
Patient registry
No

Groups and cohorts

  • Spinal Anesthesia

    Participants undergoing cesarean delivery who receive spinal anesthesia as the anesthesia technique.

    Other: Anesthesia Technique

  • General Anesthesia

    Participants undergoing cesarean delivery who receive general anesthesia as the anesthesia technique.

    Other: Anesthesia Technique

Interventions

  • OtherAnesthesia Technique

    Observed anesthesia technique in women undergoing cesarean delivery. Participants received either spinal anesthesia or general anesthesia as part of routine clinical care; the anesthesia technique was not assigned by the study.

06

What researchers measure

Primary outcomes

  1. Umbilical artery pH

    Umbilical arterial pH measured after delivery and cord clamping.

    Time frame: Immediately after delivery

Secondary outcomes

  1. Maternal venous pH

    Maternal venous pH measured immediately before anesthesia induction.

    Time frame: Immediately before anesthesia induction

  2. Umbilical artery pCO2

    Umbilical arterial pCO2 measured after delivery and cord clamping.

    Time frame: Immediately after delivery

  3. Umbilical artery pO2

    Umbilical arterial pO2 measured after delivery and cord clamping.

    Time frame: Immediately after delivery

  4. Maternal venous pCO2

    Maternal venous pCO2 measured immediately before anesthesia induction

    Time frame: Immediately before anesthesia induction

  5. Maternal venous pO2

    Maternal venous pO2 measured immediately before anesthesia induction

    Time frame: Immediately before anesthesia induction

  6. Umbilical artery HCO3

    Umbilical arterial bicarbonate measured after delivery and cord clamping.

    Time frame: Immediately after delivery

  7. Maternal venous HCO3

    Maternal venous bicarbonate measured immediately before anesthesia induction

    Time frame: Immediately before anesthesia induction

  8. Umbilical artery BE

    Umbilical arterial base excess measured after delivery and cord clamping

    Time frame: Immediately after delivery

  9. Maternal venous BE

    Maternal venous base excess measured immediately before anesthesia induction

    Time frame: Immediately before anesthesia induction

  10. Umbilical artery lactate

    Umbilical arterial lactate measured after delivery and cord clamping

    Time frame: Immediately after delivery

  11. Maternal venous lactate

    Maternal venous lactate measured immediately before anesthesia induction

    Time frame: Immediately before anesthesia induction

  12. Umbilical artery FCOHb

    Fetal carboxyhemoglobin measured in umbilical arterial blood after delivery and cord clamping

    Time frame: Immediately after delivery

  13. Maternal venous FCOHb

    Maternal carboxyhemoglobin measured in venous blood immediately before anesthesia induction

    Time frame: Immediately before anesthesia induction

  14. Maternal-fetal pH gradient (ΔpH)

    Difference between maternal venous pH and umbilical arterial pH

    Time frame: Immediately after delivery

  15. Maternal-fetal pCO2 gradient (ΔpCO2)

    Difference between maternal venous pCO2 and umbilical arterial pCO2

    Time frame: Immediately after delivery

  16. Maternal-fetal lactate gradient (Δlactate)

    Difference between maternal venous lactate and umbilical arterial lactate

    Time frame: Immediately after delivery

  17. Apgar score at 1 minute

    Apgar score assessed 1 minute after birth using the Apgar score (range, 0-10), with higher scores indicating better neonatal condition.

    Time frame: 1 minute after birth

  18. Apgar score at 5 minutes

    Apgar score assessed 5 minutes after birth using the Apgar score (range, 0-10), with higher scores indicating better neonatal condition.

    Time frame: 5 minutes after birth

  19. Neonatal intensive care unit admission

    Requirement for admission to the neonatal intensive care unit after birth

    Time frame: During the immediate neonatal period

  20. Neonatal intubation

    Requirement for endotracheal intubation after birth

    Time frame: During the immediate neonatal period

  21. Maternal hypotension requiring treatment

    Occurrence of maternal hypotension requiring pharmacologic treatment during cesarean delivery

    Time frame: From anesthesia induction until the end of surgery

  22. Maternal vasopressor requirement

    Requirement for vasopressor administration for management of maternal hypotension during cesarean delivery

    Time frame: From anesthesia induction until the end of surgery

  23. Smoking exposure and fetal FCOHb

    Association between maternal smoking exposure status and fetal carboxyhemoglobin level measured in umbilical arterial blood

    Time frame: Immediately after delivery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Dec 2026, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 6, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionApgar score at 1 minute: how it is measured was reworded
  • DescriptionApgar score at 5 minutes: how it is measured was reworded
Oct 8, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 2 updates
  1. Oct 8, 2026
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionApgar score at 1 minute: how it is measured was reworded
    • DescriptionApgar score at 5 minutes: how it is measured was reworded
    + 1 other change: conditions
  2. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861633
Lead sponsor
Bagcilar Training and Research Hospital
Responsible party
ali kahvecioğlu (DİRECTOR, Bagcilar Training and Research Hospital) — Principal investigator
First posted
Oct 6, 2026
Start date
Oct 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 8, 2026

Study contacts

Ali KAHVECİOĞLU, MD
Contact
ali.kahveci92@gmail.com
+90 5549134317
Ali KAHVECİOĞLU, MD
principal investigator · University of Health Sciences, Bağcılar Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion